Najjar, Amer M.
Manuri, Pallavi R
Olivares, Simon
Flores, Leo II
Mi, Tiejuan
Huls, Helen
Shpall, Elizabeth J.
Champlin, Richard E.
Turkman, Nashaat
Paolillo, Vincenzo
Roszik, Jason
Rabinovich, Brian
Lee, Dean A.
Alauddin, Mian
Gelovani, Juri
Cooper, Laurence J.N.
Funding for this research was provided by:
National Cancer Institute (CA141303, CA148600)
National Cancer Institute (CA116127)
Albert J Ward Foundation
Burroughs Wellcome Fund
Gillson Longenbaugh Foundation
Cancer Prevention and Research Institute of Texas
CLL Global Research Foundation
National Foundation for Cancer Research
Pediatric Cancer Research Foundation
National Cancer Institute (CA163587)
Article History
First Online: 31 May 2016
Compliance with Ethical Standards
:
: The technology described in this publication was advanced through research conducted at the University of Texas MD Anderson Cancer Center (MD Anderson) by Laurence Cooper. In January 2015, the technology was licensed by MD Anderson for commercial application to ZIOPHARM Oncology, Inc., and Intrexon Corporation, in exchange for equity interests in each of these companies. Laurence Cooper, Amer M. Najjar, Pallavi R. Manuri, Simon Olivares, Tiejuan Mi, Helen Huls, Richard E. Champlin, Brian Rabinovich, and Dean A. Lee are eligible in accordance with the Rules of Board of Regents of The University of Texas System to share in the proceeds of the disposition of the equity received by MD Anderson as a result of the licensing of this technology. On May 7, 2015, Dr. Cooper was appointed as the Chief Executive Officer at ZIOPHARM. Dr. Cooper is now a Visiting Scientist at MD Anderson where he continues to help supervise the development of this technology. The research being reported in this publication is research in which The University of Texas MD Anderson Cancer Center has an institutional financial conflict of interest. Because MD Anderson is committed to the protection of human subjects and the effective management of its financial conflicts of interest in relation to its research activities, MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and monitor the conflict of interest with respect to MD Anderson’ s conduct of this research.